Экспрессия молекулярно-биологических маркеров при немелкоклеточном раке легкого
Диссертация
Неоангиогенез или формирование новых микрососудов на основе уже существующей в ткани сети сосудов, является необходимым для роста опухоли и развития метастазов. Фактор роста эндотелия сосудов (VEGF, vascular endothelial growth factor), является главным фактором, индуцирующим образование новых сосудов в опухоли путем стимулирования деления и миграции эндотелиальных клеток близлежащих сосудов… Читать ещё >
Список литературы
- Абелев Г. И. Механизмы дифференцировки и опухолевый ростобзор). //Биохимия 2000,65: 127−138.
- Давыдов М.И., Полоцкий Б. Е. Рак легкого. //Москва, «Радикс» 1994.
- Зборовская И.Г., Татосян А. Г. Молекулярно-генетические маркерыпри раке легкого: онкогены и гены супрессоры. //Новое в терапии рака легкого. Под ред. Н. И. Переводчиковой.
- Коган Е. Межклеточные взаимодействия при опухолевом росте. Вкн. «Межклеточные взаимодествия». //Москва, «Медицина», 1995. 127−189.
- Коган Е.А., Жак Г., Кайзер У., Шилли М., Виттен А., Шурман М.,
- Шерер А., Хавеманн К Иммуногистохимия биомолекулярных маркеров рака легкого. // Архив патологии 1997, 6: 23−30.
- Коган Е.А., Мазуренко Н. Н., Юшков П. В. Тришкина Н.В., Киселев
- Ф.Л. //Иммуногистохимия клеточных онкогенов при предраке и раке легкого. Архив патологии 1990, 3−11.
- Копнин Б.П. Мишени действия онкогенов и опухолевыхсупрессоров: ключ к пониманию базовых механизмов канцерогенеза (обзор). //Биохимия 2000, 65: 5−33.
- Нормантович В.А. Рак легкого: тенденции в диагностики и лечении.
- Русский медецинский жернал 1998, 6 № 10: 635−642.
- Павлов А.С., Пирогов А. И., Трахтенберг А. Х. //Лечение ракалегкого. Москва 1979.
- Полоцкий Б.Е. Рак легкого. //Диссертация на соискание ученой степени доктора медицинских наук, Москва, 1995.
- Руководство по иммуногистохимической даигностике опухолей человека. Под редакцией С. В. Петрова, Н^Г.Райхлина. //Казань, 2000.
- Ставровская А.А. Клеточные механизмы множественной лекарственной устойчивости опухолевых клеток. //Биохимия 2000, 65: 112−126.
- Трахтенберг А.Х., Самоходский Е. В. //Диагностика и лечение начального центрального рака легкого. Хирургия 1987,9: 54−59.
- Харченко В.П., Кузьмин И В. Рак легкого. //М., Медицина, 1994.
- Чумаков П.М. Функция гена р53: выбор между жизнью и смертью (обзор). //Биохимия 2000, 65: 34−47.
- Abu-Jawdeh GM., Faix JD., NilofT J., et al. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. //Lab invest 1996, 74. 1105−1115.
- Allred DC., Harvey JM" Berardo M" Clark GM. //Mod Pathol 1998 11: 155−168.
- Anseletti CA" Lucchi M., G. Fontanini, A. Mussi, A. Chella, A. Ribechini,
- S.Vignati, G.Bevilacqua. Prognostic significance of tumoral angiogenesis in completely resected late stage lung carcinoma (stage IIIA-N2). //Cancer 78 (1996) 409−415
- Apolinario R.M., P. van der Valk, J.S.de Jong, W. Deville, J. van Ark
- Ashkenazi A., Dixit V.M. Apoptosis control by death and decoy receptors. //Curr Opin Cell Biol 1999, 11: 255−260.
- Ashkenazi A., Dixit VM. Death receptors: Signaling and modulation. //Science 1998, 281: 1305−1308.
- Ben-Ezra JM., Komstein MJ., Grimes MM., (Crystal G. Small cell carcinomas of the lung express the Bcl-2 protein. //Am J Pathol 1994 5: 1036−1040.
- Bouck N. Stellmach V., Hsu SC. How tumors become angiogenic. //Adv Cancer Res 1996,69: 135−174.
- Brambilla E. Gazzeri S., Moro D., et al. Immunohistochemical study of p53 in human lung carcinomas. //Am J Pathol 1993 143: 199−220.
- Brambilla E., Nagoescu A., S. Gazzeri, S. Lantuejoul, D. Moro,
- C.Brambilla, J-L Coll. Apoptosis-related factors p53, Bcl-2, and Bax in neuroendocrine lung tumors. //Am. J. Pathol. 149(1996) 1941−1952)
- Brown LF., Gaudi AJ., Schnitt SJ., et al. Vascular permeability factor/vascular endothelial growth factor and vascular stroma formation in neoplasia: insights from in situ hibridisation studies. //J Histochem Cytochem 1998,46: 569−575.
- Bull HA., Brickell PM., Dowd PM. Scr-related protein tyrosine kinases are physically associated with the surface antigen CD36 in human dermal microvascular endothelial cells. //FEBS Lett 1994, 351: 41−44.
- Caamano J., Ruggeri B., Momiki S., Sickler A., Zhang SY., Klein-Szanto AJP. Detection of p53 in primaty lung tumors and non-small-cell lung carcinoma cell lines. //Amer J Pathol 1991, 139: 839−845.
- Chambers AF., Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. //J Natl Cancer Inst 1997, 89: 12 601 270.
- Chen Y, Sato M., Fujimura S., et al. Expression of Bcl-2, Bax and p53 proteins in cancerogenesis of squamous cell lung cancer. //Anticancer Res 1999,19: 1351−1356.
- Cheng E.H.-Y., Kirsch D.G., R.J.Clem, R. Ravi, M.B.Kastan, S. Bedi,
- K.Ucno, J. M. Hard wick Conversion of Bcl-2 to a Bax-like death effector by caspases. //Science 278 (1997) 1966−1968.
- Chinnaiyan AM., Prasad U., Shankar S., Hamstra DA., Shanaiah M., Chenevert TL., Ross BD., Rehemtulla A. //Proc Natl Acad Sci USA 2000, 97:1754−1759.
- Costa A., R. Silvestrini, C. Mochen, C. Lequagle, P. Borrachi, A. Faranda, G. Vessecchia, G.Ravasi. P53 expression, DNA ploidy and S-phase cell fraction in operaleble loccally advanced non-small-cell lung cancer. //Br.J. Cancer. 73 (1996) 914−919
- Coussens LM., Werb Z. Matrix metalloproteinases and the development of cancer. //Chem Biol 1996, 3: 895−904
- Craft PS., AL.Harris. Clinical prognostic significance of tumourangiogenesis. //Ann.Oncol.5 (1994) 305−311.
- Dameron K., O. Volpert, M. Tainski, N.Bouck. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-l. //Science 265 (1994) 1582−1584.
- Dameron KM., Volpert OV., Tainsky MA., Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-l. //Science 1994, 265: 1582−1584.
- Dive C., Hickman JA. Drug-target interactions: only the first step in the commitment to a programmed cell death? //Br. J. Cancer 1991, 64: 192−196.
- Dive C., Hickman JA. Drug-target interactions: only the first step in thecommitment to a programmed cell death? //Br. J. Cancer 64, 192−196 (1991).
- Elstein K. H., et al. Factors affecting flow cytometric detection of apoptotic nuclei by DNA analysis. //Cytometry 21. 170−176 (1995)
- Evan GE., Brown L" Whyte M" Harrington E. //Curr Opin Cell Biol 1995, 7. 825−834.
- Fadok V. A., et al. Exposure of phosphotidylserin on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. //J. Immunol. 148. 2201−2216 (1992)
- Fedi P., Tronick SR., Aaronson SA. Growth factors. In Cancer Medicine, JF. Holland, RC. Bast, DL. Morton, E. Frei, DW. Kufe, RR. Weichselbaum, eds. //(Baltimore, MD: Williams and Wilkins). 1997:41−65.
- Finlay CA. P53 loss of function implications for the processes of immortalization and tumorigenesis VBioessays 1992, 14:557−560.
- Foley KP, Eisenman RN. Two MAD tails: what the recent knockouts of Madl and Mxl tell us about the MYC/MAX/MAD network. //Biochem Biophys Acta 1999, 1423: M37−47.
- Folkman J. Tumor angiogenesis. In Cancer Medicine, JF. Holland, RC. Bast, DL. Morton, E. Frei, DW. Kufe, RR. Weichselbaum, eds. //(Baltimore, MD: Williams and Wilkins). 1997: 181−204.
- Fontanini G., D. Bigini, S. Vignati, F. Basolo, A. Mussi, M. Lucchi,
- S.Chine, CA. Angeleti, AL. Harris, G.Bevilacqua. Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. //J. Pathol. 177(1995)57−63.
- Fontanini G., S. Vignati, D. Vigini, A. Mussi, M. Lucchi, C.A.Angeletti,
- F.Basolo, G.Bevilacqua. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. //Br. J. Cancer 71 (1995) 1003−1007.
- Fontanini G., Vignati S., Lucchi M, et al. Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression. //Br J Cancer 1997, 75: 1295−1301.
- Fraizier W., C. Prater, D. Jaye, M. Kosfeld. Interactions of thrombospondin with cells. Thrombospondins: biological function for structural motifs. In: J. Lahav (ed.), //Thrombospondin. CRC Press, Boca Raton, FL pp. 91−109 (1993)
- Fukushige S., K. Matsubara, M-C.Yoshida et al. Localization of a novel v-erbB related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. //Mol.Cell. Biol. 6 (1986) 955−958.
- Fulda S., et al. The CD95 (APO-l/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. //Cancer Res. 57, 3823−3829 (1997)
- G.Casey, M.E.Lopez, J.C.Ramos, S.J.Plummer, M.J.Arboleda,
- M.Shaughnessy, B. Karl an, D.J.Slamon. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required tod iect all known p53 alterations in human malignancies. //Oncogene 13 (1996) 1971−1981.
- Gasparini G., Pozza F, Harris AL. Evaluating the usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. Hi Natl Cancer Inst 1993, 85: 1206−1219.
- Gazzeri S., Brambilla E., Caron de Fromentel C., Gouyer V., Moro D., Perron P., Berger F., Brambilla C. p53 genetic abnormalities and myc activation in human lung carcinoma. //Int J Cancer 1994, 58: 24−32.
- Giatromanolaki A., M. Kuokuorakis, K. O'Byme, S. Fox, R. Whitehouse,
- D.Talbot, AL. Harris, KC.Gatter. Angiogenesis is a significant prognostic marker in operable non-small cell lung cancer. //J. Pathol. 179(1995) 80−88.
- Gibson SB., Oyer R., Spalding AC., Anderson SM., Johnson GL. //Mol Cell Biol 2000, 20: 205−212.
- Golstein P. //Curr. Biol. 1997. 7: 27−59
- Gorczyca W. et al. The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. //Cancer Res. 53.3186−3192 (1993)
- Graziano S. Non-small cell lung cancer: clinical value of new biologicalpredictors. //Lung Cancer 17 (1997) 37−58.
- Green DR, Reed JC. Mitochondria and apoptosis. //Science 1998, 281:1309−1312.
- Greenblatt M S., W.P.Bennett, MK. Hollstein, C.C.Harris. Mutations inthe p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. //Cancer Res. 54 (1994)4855−4878.
- Hayflick L. Mortality and immortality at the cellular level. A review. //Biochemistry 1997, 62: 1180−1190.
- Higashiyama M., O. Doi, K. kodama, H. Yokouchi, S. Nakamori,
- R.Tateishi. bcl-2 oncoprotein in surgically resected nonsmall cell cancer: possibly favorable prognostic factor in association with low incidence of distant metastasis. //J.Surg.Oncol. 64 (1997) 48−54.
- Hiyoshi H., Matsuno y., Kato H., Shimasato Y., Hirohashi S. Clinicopathological significance of nuclear accumulation of tumor-suppressor gene p53 product in primary lung cancer. //Jap J Cancer Res 1992, 83: 101−106.
- Iggo R., Gatter K., Bartek J., Lane D., Harris AL. Increased expression o mutant forms of p53 oncogene in phimary lung cancer. //Lancet 1990, 335: 657−659.
- Itoh N. et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. //Cell 66, 233−243 (1991)
- Itoh N" Nagata S. A novel protein domain required for apoptosis: mutational analysis of human Fas antigen. Hi. Biol. Chem. 268, 10 932−10937(1993)
- Jiang S.X., T. Kameya, Y. Sato, N. Yanase, H. Yoshimura, T.Kodama.
- Bcl-2 protein expression in lung cancer and close correlation with neuroendocrine differentiation. //Am.J.Pathol. 148 (1996) 837−846.
- Jiang S.X., Y. Sato, S. Kuwao, T.Kameya. Expression of bcl-2 oncogeneprotein is prevalent in small cell carcinomas. //J Pathol 177 (1995) 135−138.
- Johnson JP. Cell adhesion molecules of the immunoglobin supergene family and their role in malignant transformation and progression of metastatic disease. //Cancer Metastasis Rev 1991, 10: 11−22.
- Kaiser U., M. Schilli, U. Haag, K. Neumann, H. Kreipe, E. Kogan,
- K.Havemann. Expression of bcl-2-protein in small cell lung cancer. //Lung Cancer 15 (1996) 31−40.
- Kalra R., AM. Jones, J. Kirk, GE. Adams, U.Stratford. The effect ofhipoxia on acquired drug resistance and response to epidermal growth factor in Chinese lung fibroblasts and human breast cancer cells in vivo. //Int J. Cancer 54 (1993) 650−655.
- Kawai T., M. Suzuci, S. Kono, N. Shinomiya, M., Rocutanda, K. Takagi, T. Ogata, S.Tamai. Proliferating cell nuclear antigen and Ki-67 in lung carcinoma. //Cancer 74 (1994) 2468−2475.
- Kawai T., Suzuki M., Kono S., Shinomiya N., Rokutana m., Takagi K, Ogata T., Tamai S. Proliferating cell nuclear antigen and Ki-67 in lung carcinoma. Correlation with DNA flow cytometric analysis. //Cancer 1994, 74. 2468−2475.
- Kawasaki M., Y. Nakanishi, J. Yatsunami, K. Takayama, S. Ochiai, P. Xinhai, K. Kuwano, N.Hara. p53 immunostaining predictive chemosensitivity in non-small cell lung cancer: a preliminary report. //Cancer J. Sci. Am. 4 (1996) 217.
- Kawasaki M., Y. Nakanishi, J. Yatsunami, K. Takayama, S. Ochiai, P. Xinhai, K. Kuwano, N.Hara. p53 immunostaining predictive chemosensitivity in non-small cell lung cancer: a preliminary report. //Cancer J. Sci. Am. 4 (1996) 217.
- Kawasaki M., Y. Nakanishi, K. Kuwano, K. Takayama, C. Kiyohara, N.Hara. Immunohistohemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer. //Eur.J.Cancer 9 (1998) 1352−1357.
- Kern J A., R J.C.Slebos, B. Top, S. Rodenhuis, D. Ladger, R.A.Robinson,
- D.Weiner, D.A.Schwartz. C-erbB-2 expression and codon 12 K-ras mutations both prdict shortened survival for patients with pulmonary adenocarcinomas. //J.Clin.Invest. 93 (1994) 516−520.
- Keurbitz SJ., BS. Plunkett, WV. Walsh, MB.Kastan. Wild-type p53 is a cell cycle check-point determinant following irradiation. //Proc. Natl.Acad. Sei. USA 89 (1992) 7492−7496.
- Kischkel F., et al. Cytotoxicity-dependent APO-l (Fas/CD95)-associated proteins from a death-inducing signaling complex (DISC) with the receptor. //EMBO J. 14, 5579−5588 (1995)
- Kishimoto Y., Murakami Y., Shiraishi M., Hayashi K., Sekiya T. Aberrations of the p53 tumor-suppressor gene in human non-small-cell carcinomas of the lung. //Cancer Res 1992, 53: 4799−4804.
- Kitagawa Y., F. Wong, P. Lo, M. Elliott, L.M.Verburgt, J.C.Hogg, M.Daya. Overexpression of Bcl-2 and mutations in p53 and K-ras in resected human non-small cell lung cancers. //Am.J.Respir.Cell.Mol.Biol. 15 (1996) 45−54.
- Koomagi R., Volm M. Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance. //Int J Cancer 1999, 84(3): 239−243.
- Koopman G., et al. AnnexinV for flow cytometric detection of phosphatidylserine expression of B cell undergoing apoptosis. //Blood. 84. 1415−1420(1994)
- Kubota Y" RE. Petras, KA. Easley, TW. Bauer, RR. Tubbs, VW.Fazio. Ki-67-determined growth fraction versus standard staining and grading parameters in colorectal carcinoma: a multivariate analysis. //Cancer 70(1992) 2602−2609.
- Lanny J., S. Lowe, E. Licitra, J. Liu, T.Jacks. p53-independent apoptosis induced by paclitaxel through an indirect mechanism. //Proc. Natl. Acad. Sci. USA 94 (1997) 9679−9683.
- Leech SH., Olie RA., Gautschi O, et al. Induction of apoptosis in lung-cancer cells following bcl-xL antisense treatment. //Int J Cancer 2000, 15:570−576.
- Leedy DA., DR. Trune, JD. Kronz, N. Weidner, JI. Cohen. Tumorangiogenesis< the p53 antigen and cervical metastasis in squamous carcinoma. //Otolaringol. Head Neck Surg. 111 (1994) 417−422.
- Levine A.J. p53, the cellular gatekeeper for growth and division. //Cell88(1997) 323−331.
- Lotem J., Sachs L. Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and oncogenes. //Leukemia 1996, 10: 925−931.
- Macchiarini P., G. Fontanini, MJ. Hardin, F. Squartini, CA.Angeletti.
- Relation of neovascularisation to metastasis of small cell lung cancer. //Lancet 340(1992) 145−146.
- Maclusky M, Baillie R, Chandrachud LM., Pendelton N., Schor AM. High levels of apoprosis are associated with impruved survival in non-small cell lung cancer. //Anticancer Res. 2000, 20: 2123−2128.
- Mattern J., Koomagi R., Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. //Br.J.Cancer 73 (1996) 931−934.
- Mattern J., Koomagi R., Volm M. Coexpression of VEGF and bFGF in human epidermoid lung carcinoma is associated with increase vessel density. //Anticancer Res. 17 (1997) 2249−2252.
- McLaren R., Kuzu I., Dunnill M., Harris A., Lane D., Gatter KC. The relationship of p53 immunostaining to survival in carcinoma of the lung. //Br J Cancer 1992,66. 735−738.
- Mekori Y. A., et al. IL-3 dependent murine mast cells undergo apoptosis on removal of 11−3. Prevention of apoptosis by c-kit ligand //J. Immunol. 151. 3775−3784(1993)
- Micheau O., E. Solary, A. Hammann, F. Martin, M.T.Dimanche-Boitrel. Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. //J.Natl.Cancer Inst. 89/11 (1997) 783−789
- Micheau O., Solary E., Hammann A., Martin F., Dimanche-Boitrel M.T. Sensitization of cancer cells treated with cytotoxic drugs to fasmediated cytotoxicity. //J.Natl.Cancer Inst. 1997, 89/11: 783−789.
- Mitsudomi T., Oyama T., Kusano T., Nakanishi R., Shirakusa T. Mutations of the p53 gene as predictor of poor prognosis in patients with non-small-cell lung cancer. Hi Natl Cancer Inst 1993, 85: 20 182 023.
- Ohta Y., Y. Watanabe, S. Murakami, M. Oda, Y. Hayashi, A. Nonomura, Y. Endo, T.Sasaki. Vascular endothelial growth factor and lymph node metastisis in primary lung cancer. //Br.J.Cancer 76 (1997) 1041−1045.
- Oshika Y., M. Nakamura, T. Tokunaga, Y. Fukushima, Y. Abe, Y. Ozeki, H. Tamaoki, Y.Ueyama. Multidrug resistance-associated protein and mutant p53 protein expression in non-small cell lung cancer. //Mod.Pathol. 11 (1998) 1059−1063.
- Passlick B., Izbicki JR., Riethmuller G., et al. P53 in non-small cell lung cancer. //J Natl Cancer Inst 1994 86: 801−802.
- Pepper MS., N. Ferrara, L. Orci, R.Montesano. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. //Biochem.Biophys.Res. Commun. 189 (1992) 824−831.
- Perdomo JA., Y. Naomoto, M. Haisa, T. Fujiwara, M. Hamada, Y. Yasuoka, N.Tanaka. In vivo influence of p53 status on proliferation and chemoradiosensitivity in non-small-cell lung cancer. //J. Cancer Res. Clin. Oncol. 124 (1998) 10−18.
- Pezzella F., H. Turley, I. Kuzu, M.F.Tungekar, M.S.Dunnil, C.B.Pierce, A. Harris, K.C.Gatter, D.Y.Mason, bcl-2 protein in non-small-cell lung carcinoma. //New Engl.J.Med. 329 (1993) 690−694.
- Pittu RM., Marsters SA., Ruppert S., Donahue CJ., Moore A., Ashkenazi A. //J Biol Chem 1996, 271: 12 687−12 690.
- Quinlan DC., Davidson AG., Summers CL" Warden HE., Doshi HM. Accumulation of p53 protein correpates with a poor prognosis in human lung cancer. //Cancer Res 1992, 52. 4828−4831.
- Rachwal W.J., P.F.Bongiomo, M.B.Orringer, R.l.Whyte, S P Ethier, D.G.Beer. Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas. //Br.J.Cancer 72 (1995) 5664.
- Rice GC., V. Ling, RT.Schimke. Frequencies of independent and simultaneous selection of Chines hamster cells for methotrexate and doxorubicin (adriamicin) resistance. //Proc. Natl. Acad Sci. USA 84 (1987) 9261−9264.
- Scheurle D., Jahanzeb M., Aronsohn RS., Narayanan R. Her-2/neu expression in archival cell lung carcinomas using FDA-approved HercepTest. //Anticancer Res 2000, 20:3B 2091−2096.
- Schneider P.M., M.-C.Hung, S.M.Chiocca, J. Manning, X. Zhao, K. Fang, J.A.Roth. Differential expression of the c-erb B-2 gene in human small cell and non-small cell lung cancer. //Cancer Res. 49 (1989) 4968−4971
- Schwarting R. Little missed markers and Ki-67. //Lab. Invest. 68 (1993) 597−599.
- Shi D" He G" Cao S" Pan W" H.Z.Zhang, D. Yu, M.C.Hung. Overexpression of the c-erb B-2/neu-encoded p 185 protein in primary lung cancer. //Mol.Carcinogen. 5 (1992) 213−218.
- Shimasato Y. Pathology: Revised classification of epithelial tumors of the lung (WHO/IASLC). //In: Textbook of Lung Cancer. H.H.Hansen, ed. London, England, Martin Dunnitz, 2000, 125−140.
- Simony J., J-L. Pujol, M. Radal, E. Ursule, F-B.Michel, H.Pujol. In situ evaluation of growth fraction determined by monoclonal antibody Ki-67 and ploidy in surgically resected non-small cell lung cancers. //Cancer Res. 30 (1990) 4382−4387.
- Simony J., Pujol J-L., M. Radal, E. Ursule, F-B.Michel, H.Pujol. In situ evaluation of growth fraction determined by monoclonal antibody Ki-67 and ploidy in surgically resected non-small cell lung cancers. //Cancer Res. 50 (1990) 4382−4387.
- Solary E., Micheau O., Dimanche-Boitrel M.T. Role of the Fas/Fas-L system in the immune response to tumors and the resistance to cytotoxic drugs. //Bulletin du Cancer 1998, 85/8: 685−694.
- Sporm MB. The war on cancer.// Lancet 1996, 347: 1377−1381.
- Suzuki H., Takahashi T., Kurioshi T., Suyama M., Ariyoshi Y., Ueda R. p53 mutations in non-small-call lung cancer in Japan: association between mutations and smoking. //Cancer Res 1992, 52: 734−736.
- Takahashi T. et al. Swapping between Fas and G-CSF receptor. Hi. Biol. Chem., in press.
- Takanami 1., T. lmamura, T. Hashizume, K. Kikachi, Y. Yamamoto, T. Yamamoto, S.Kodaira. //Immunohistochemical detection of basic fibroblast growth factor as prognostic indicator in pulmonary adenocarcinoma. Jpn.J.Clin.Oncol. 26 (1997) 293−297.
- Tanaka F., Kawano Y., Li M., et al. Prognostic significance of apoptotic index in completely resected non-small cell lung cancer. //J Clin Oncol 1999, 17: 2728−2736.
- Tateishi M., T. Ishida, T. Mitsudomi, S. Kaneko, K.Sugimachi. Prognostic value of c-erb B-2 protein expression in human lungadenocarcinoma and squamous cell carcinoma. //Eur.J.Cancer 27 (1991) 1372−1375.
- Teitz T., Wei T., Valentine MB., Vanin EF., Grenet J., Valentine VA., Behm FG" Look AT., Lahti AT., Kidd VJ. //Nature Med 2000, 6: 529 535.
- Tolsma S., O. Volpert, D. Good, W. Frazier, P. Polverini, N.Bouck. Peptides from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. //J. Cell Biol. 122 (1993)497−511.
- Top B., Mooi WJ, klaver SG" Boerrigter L., Wisman P., Elbers H., Visser S., Rodenhuis S. Comparative analysis of p53 gene mutations and protein accumulation in human non-small-call lung cancer, //lnt J Cancer 1995, 64: 83−91.
- Tugekar MF, KC. Gatter, MS. Dunnill, DY Mason. Ki-67 immunostaining and survival in operable lung cancer. //Histopathology 19(1991)545−550.
- Volm M, Koomagi R. Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patients survival. //Br J Cancer 2000, 82(10): 1747−1754.
- Volm M., Koomagi R. The implication of proliferation and apoptosis for lung cancer metastasis. //Oncol rep 1999, 6(2). 373−376.
- Volm M., R. Koomagi, J. Mattern, G.Stammler. Prognostic value basic fibroblast growth factor and its receptor (FGFR-1) in patients with non-small cell lung carcinomas. //Eur. I. Cancer 33 (1997) 691−693.
- Volm M., R. Koomagi, J.Mattern. Prognostic value of vascular endothelial growth factor and its receptor Fit-1 in squamous cell lung cancer. //Int.J.Cancer 74 (1997) 64−68.
- Volm M., R.Koomagi. The implication of proliferation and apoptosis for lung cancer metastsisis. //Oncol. Rep. 2 (1999) 373−376
- Walczak H" Miller RE., Ariail K" Gliniak B" Griffith TS, Kubin M" Chin W., Jones J., et al. //Nature Med 1999, 5: 157−163.
- Walker C., Robertson L., Myskow M., Dixon G. Expression of the Bcl-2 protein in normal and displastic bronchial epitelium and lung carcinomas. //Br J Cancer 1995 1: 164- 169.
- Weidner N. Intratumor microvessel density as a prognostic factor in cancer. //Am. J. Pathol. 147 (1995) 9−19.
- Weidner N. Tumour angiogenesis: review of current applications in tumour prognostication. //Semin. Diagn. Pathol. 10 (1993) 302−313.
- Weiner D.B., Nordberg J., Robinson R" Nowell P C., A. Gazdar, M.I.Greene, W.V.Williams, J.A.Cohen, J.A.Kern. Expression of the neu gene-encoded protein (PISS1™) in human non-small cell carcinomas of the lung. //Cancer Res. 50 (1990) 421−425.
- Yamaziki K., S. Abe, H. Takekawa, N. Sukoh, N. Watanabe, S. Ogura, I. Nakajima, H. Isobe, K. Inoue, Y Kawakami Tumor angiogenesis in human lung carcinoma. //Cancer 74 (1994) 2245−2250.
- Yu D, Wang S.-S., Dulski K M., Tsai C.-M., G.L.Nicolson, M.-C.Hung. c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. //Cancer Res.54 (1994) 3260−3266.
- Zabrenetzky V., C. Harris, P. Steeg, D.Roberts. Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. //Int.J.Cancer 59 (1994) 191−195.0